---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037816"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:58:53.060065+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ChromaDex reports Q3 2023 net sales $19.5M (+14% YoY), positive adjusted EBITDA $0.5M

## Summary
- Total net sales $19.5M (+14% YoY); Tru Niagen sales $17.4M (+19% YoY).
- Gross margin 61.4% (up 160 bps); net loss $1.0M ($0.01 loss per share).
- Adjusted EBITDA positive $0.5M, a $1.7M improvement from Q3 2022.
- Cash $26.8M, no debt; positive operating cash flows for third consecutive quarter.
- Launched Tru Niagen on iHerb in Aug; launched 1,000mg dosage in Oct; Zesty Paws partnership.

## SEC filing metadata
- accession: 0001628280-23-037816
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828023037816/0001628280-23-037816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828023037816/cdxc-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037816
- JSON: https://secwatch.observer/filing/0001628280-23-037816.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037816.txt

## Key facts
- Earnings Releases
  Niagen Bioscience, Inc. reported the third quarter of 2023 results: revenue $19.5 million, net income $1.0 million, EPS $(0.01) per share.
  - Period: the third quarter of 2023
  - Revenue: $19.5 million
  - Net income: $1.0 million
  - EPS: $(0.01) per share
  - Result: reported results
  source text: ChromaDex Corporation Reports Third Quarter 2023 Financial Results Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000162828023037816/0001628280-23-037816-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.